Gynecologist and geneticist Noah Kauff commented on a study that found that women diagnosed with uterine cancer may have a higher risk of developing colon cancer later in life. He said the increased risk could be due to women with a hereditary condition known as Lynch syndrome.
Visible Ink founder Judith Kelman discussed the Memorial Sloan-Kettering program she runs that connects patients with experienced writers, editors, and teachers to help them tell their stories in writing. A Memorial Sloan-Kettering patient and program participant was also interviewed.
Integrative Medicine Service Chief Barrie Cassileth commented on the importance of informing your doctor of all medicines you take, including supplements.
Endocrinologist James Fagin spoke about a study he led that found that an investigational drug may help some patients with thyroid cancer who are unable to absorb radioactive iodine, the most effective therapy for the disease.
Victor Ribaudo, Executive Director of Memorial Sloan-Kettering’s Regional Care Network, spoke about plans to open a new suburban outpatient treatment center in Middletown, New Jersey.
Hematologist-oncologist Sergio Giralt was interviewed about treating Good Morning America co-host Robin Roberts, who received a stem cell transplant at Memorial Sloan-Kettering.
Medical oncologist Leonard Saltz and epidemiologist Peter Bach commented on Memorial Sloan-Kettering’s decision not to carry a new colorectal cancer drug due to its cost.
Director of Memorial Sloan-Kettering’s Male Sexual and Reproductive Medicine Program John Mulhall discussed ways to improve sexual function after prostate cancer surgery.
Medical oncologist Larry Norton discussed cancer advances made possible by collaborative efforts like those described in a recent TIME magazine article.
Medical oncologist Renier Brentjens was interviewed about a study he co-led with cell researcher Michel Sadelain that found that genetically modified immune cells were able to induce complete remissions in patients with advanced B cell acute lymphoblastic leukemia.
Medical oncologist Renier Brentjens and cell researcher Michel Sadelain reported for the first time that genetically modified immune cells were able to induce complete remissions in all five patients treated with the experimental therapy. Patients had advanced B cell acute lymphoblastic leukemia, a disease with limited treatment options.
Medical oncologist Howard Scher commented on an investigational microchip that can count and sort cancer cells so doctors can determine how well treatments are working.
Epidemiologist Talya Salz commented on a study that found that women experience significant stress when called for follow-up after a routine mammogram, and that the stress lasts long after follow-up tests show no signs of cancer.
